MX2024009496A - Granulos de manitol directamente compresibles. - Google Patents
Granulos de manitol directamente compresibles.Info
- Publication number
- MX2024009496A MX2024009496A MX2024009496A MX2024009496A MX2024009496A MX 2024009496 A MX2024009496 A MX 2024009496A MX 2024009496 A MX2024009496 A MX 2024009496A MX 2024009496 A MX2024009496 A MX 2024009496A MX 2024009496 A MX2024009496 A MX 2024009496A
- Authority
- MX
- Mexico
- Prior art keywords
- directly compressible
- mannitol granules
- compressible mannitol
- granules
- relates
- Prior art date
Links
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 title abstract 2
- 229930195725 Mannitol Natural products 0.000 title abstract 2
- 239000008187 granular material Substances 0.000 title abstract 2
- 235000010355 mannitol Nutrition 0.000 title abstract 2
- 239000000594 mannitol Substances 0.000 title abstract 2
- 238000007907 direct compression Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2201119A FR3132522B1 (fr) | 2022-02-08 | 2022-02-08 | Granules de mannitol directement comprimable |
| FR2211326 | 2022-10-28 | ||
| PCT/EP2023/025057 WO2023151868A1 (fr) | 2022-02-08 | 2023-02-08 | Granules de mannitol directement comprimables |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009496A true MX2024009496A (es) | 2024-08-19 |
Family
ID=85278534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009496A MX2024009496A (es) | 2022-02-08 | 2023-02-08 | Granulos de manitol directamente compresibles. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250134816A1 (https=) |
| EP (1) | EP4475821A1 (https=) |
| JP (1) | JP2025505542A (https=) |
| KR (1) | KR20240138086A (https=) |
| AU (1) | AU2023217824A1 (https=) |
| CA (1) | CA3251212A1 (https=) |
| MX (1) | MX2024009496A (https=) |
| WO (1) | WO2023151868A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3126683B2 (ja) * | 1996-04-16 | 2001-01-22 | 武田薬品工業株式会社 | Ｄ−マンニトールおよびその製造法 |
| DE10161402A1 (de) * | 2001-12-13 | 2003-06-18 | Merck Patent Gmbh | Verfahren zur Herstellung von direkt tablettierbarem beta-Mannit |
| BRPI0914164B1 (pt) * | 2008-06-20 | 2019-04-30 | Merck Patent Gmbh | Comistura para produção de comprimidos de desintegração rápida em um processo de formação de comprimido direto, seus usos, e formulações de comprimido |
| FR2944971B1 (fr) * | 2009-04-30 | 2012-09-07 | Roquette Freres | Coagglomerats de mannitol et d'amidon granulaire comprimables et a ecoulement libre |
| FR3038836B1 (fr) * | 2015-07-17 | 2017-07-14 | Roquette Freres | Granules de mannitol pour compression directe |
-
2023
- 2023-02-08 AU AU2023217824A patent/AU2023217824A1/en active Pending
- 2023-02-08 KR KR1020247026730A patent/KR20240138086A/ko active Pending
- 2023-02-08 WO PCT/EP2023/025057 patent/WO2023151868A1/fr not_active Ceased
- 2023-02-08 MX MX2024009496A patent/MX2024009496A/es unknown
- 2023-02-08 JP JP2024544993A patent/JP2025505542A/ja active Pending
- 2023-02-08 EP EP23705482.0A patent/EP4475821A1/fr active Pending
- 2023-02-08 CA CA3251212A patent/CA3251212A1/en active Pending
-
2024
- 2024-02-08 US US18/836,792 patent/US20250134816A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4475821A1 (fr) | 2024-12-18 |
| WO2023151868A1 (fr) | 2023-08-17 |
| US20250134816A1 (en) | 2025-05-01 |
| AU2023217824A1 (en) | 2024-08-01 |
| JP2025505542A (ja) | 2025-02-28 |
| KR20240138086A (ko) | 2024-09-20 |
| CA3251212A1 (en) | 2023-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019013707A2 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson | |
| MX2021013476A (es) | Composiciones de pienso para animales y uso de las mismas. | |
| UY28760A1 (es) | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotrópico | |
| CL2023002712A1 (es) | Composiciones cementicias y métodos relacionados | |
| CL2015001696A1 (es) | Compuestos derivados de 3,5-diamino-6-cloropirazin-2-carboxamida, bloqueadores de los canales de sodio epiteliales; composicion farmaceutica; metodos para bloquear canales de sodio y para promover la hidratacion de las mucosas; metodo de tratamiento; y uso para el tratamiento del asma, bronquitis y piel seca, entre otros. | |
| MX2021000328A (es) | Enzimas de variantes de galactosa oxidasa modificadas geneticamente. | |
| AR109612A1 (es) | Proceso y catalizador para preparar 1,4-butanodiol | |
| CO2024000890A2 (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington | |
| BR112019003987A2 (pt) | formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc | |
| BR0211761A (pt) | depsipeptìdeos e processos para preparar os mesmos | |
| MX2022013396A (es) | Compuestos de tetrahidroisoquinolina como activadores de nrf2. | |
| MX389438B (es) | Granulos de manitol para compresion directa. | |
| BR112021014944A2 (pt) | Toxinas apxia, apxiia e apxiiia inativas | |
| ECSP21082195A (es) | Formas sólidas de un inhibidor de glyt1 | |
| MX2018001881A (es) | Deshidratacion catalitica de acido hidroxipropionico y sus derivados. | |
| MX2022012740A (es) | Composicion de fragancia. | |
| CL2019002629A1 (es) | Análogos de deutetrabenazina, su preparación y uso. | |
| MX2017000829A (es) | Composiciones de azucares para la formacion de comprimidos mediante compresion directa. | |
| CO2024010803A2 (es) | Compuestos de tienopirrolotriazina, su preparación y su uso terapéutico | |
| MX2024009496A (es) | Granulos de manitol directamente compresibles. | |
| BR112021013206A2 (pt) | Bibliotecas de peptídeos e respectivos métodos de uso | |
| MX2022013398A (es) | Compuestos de tetrahidroisoquinolina como activadores de nrf2. | |
| BR112021021142A2 (pt) | Composições de cimento autoclavado | |
| CL2020001494A1 (es) | Uso de una proteína no estructural de prv para proteger contra la inflamación del músculo esquelético y cardíaco. | |
| ECSP034532A (es) | Derivados del 1-aminobutan-3-ol sustituido |